Research Article
Pulmonary Arterial Hypertension Specific Therapy in Patients with Combined Post- and Precapillary Pulmonary Hypertension
Table 1
Descriptive statistics of patients enrolled in the study.
| Variable | Patients who tolerated PAHST | Patients who did not tolerate PAHST | Number of patients | Mean | SE | Number of patients | Mean | SE |
| Age | 20 | 64.6 | 2.93 | 6 | 67.4 | 4.61 | CCI | 20 | 3.80 | 0.36 | 6 | 4.0 | 0.37 | PAPm | 20 | 51.3 | 2.71 | 6 | 48.8 | 3.45 | PAWP | 20 | 23.6 | 0.84 | 6 | 27.0 | 2.80 | TPG | 20 | 27.7 | 2.53 | 6 | 21.8 | 2.27 | PVR | 19 | 6.5 | 0.78 | 6 | 7.14 | 2.47 | DPG | 20 | 8.3 | 1.65 | 6 | 4.2 | 2.06 | CO | 19 | 4.46 | 0.21 | 6 | 3.68 | 0.25 | Vascular compromise | 19 | 71.2 | 1.20 | 6 | 71.4 | 2.47 |
| WHO-baseline | 20 | 2.70 | 0.21 | 6 | 3.00 | 0.37 | WHO-3 months | 18 | 2.33 | 0.23 | | | | WHO-6 months | 18 | 2.22 | 0.21 | | | | WHO-9 months | 16 | 2.06 | 0.21 | | | | 6-MWD-baseline | 23 | 276.0 | 38.50 | 6 | 268.0 | 50.52 | 6-MWD-3 months | 17 | 360.5 | 29.01 | | | | 6-MWD-6 months | 17 | 343.9 | 22.99 | | | | 6-MWD-9 months | 15 | 364.6 | 34.85 | | | | 6-MWD (% pre)-baseline | 23 | 56.4 | 6.83 | 6 | 58.3 | 8.99 | 6-MWD (% pre)-3 months | 17 | 72.6 | 3.82 | | | | 6-MWD (% pre)-6 months | 17 | 72.8 | 3.58 | | | | 6-MWD (% pre)-9 months | 15 | 74.1 | 4.26 | | | | Survival (in days) | 20 | 1350.8 | 173.44 | | | |
|
|
PAHST = Pulmonary Arterial Hypertension Specific Therapy, CCI = Charlson Comorbidities Index, PAPm = Mean Pulmonary Artery Pressure (mmHg), PAWP = Pulmonary Arterial Wedge Pressure (mmHg), CO = Cardiac Output (L/min), TPG = Transpulmonary Gradient (mmHg), DPG = Diastolic Pressure Gradient (mmHg), PVR = Pulmonary Venous Resistance (WU), WHO = World Health Organization functional class, 6-MWD = 6-minute walk distance (meters), and SE = standard error. |